Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 20/20 | 0.60 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.60 |
| ▸ | TSPO | P30536 | 1/20 | 0.60 |
| ▸ | BRD2 | P25440 | 4/20 | 0.51 |
| ▸ | BRDT | Q58F21 | 4/20 | 0.49 |
| ▸ | BRD3 | Q15059 | 3/20 | 0.49 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.49 |
| ▸ | JAK2 | O60674 | 1/20 | 0.49 |
| ▸ | BRD1 | O95696 | 1/20 | 0.49 |
| ▸ | CCL2 | P13500 | 1/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.49 |
| ▸ | EP300 | Q09472 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | DNER | Q8NFT8 | 1/20 | 0.49 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.49 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.49 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23728703 | 0.90 | BRD4 (0.60) | BRD4ADORA3TSPOBRD2BRDT | |
| SCHEMBL30320662 | 0.90 | BRD4 (0.60) | BRD4ADORA3TSPOBRD2BRDT | |
| SCHEMBL18199905 | 0.89 | BRD4 (0.64) | BRD4ADORA3TSPOBRD2BRDT | |
| SCHEMBL881486 | 0.89 | BRD4 (0.64) | BRD4ADORA3TSPOBRD2BRDT | |
| SCHEMBL23728722 | 0.89 | BRD4 (0.58) | BRD4ADORA3TSPOBRD2BRDT | |
| SCHEMBL871494 | 0.89 | BRD4 (0.58) | BRD4ADORA3TSPOBRD2BRDT | |
| SCHEMBL19465639 | 0.87 | BRD4 (0.55) | BRD4ADORA3TSPOBRD2BRDT | |
| SCHEMBL19172521 | 0.87 | BRD4 (0.55) | BRD4ADORA3TSPOBRD2BRDT | |
| SCHEMBL881270 | 0.80 | BRD4 (0.64) | BRD4ADORA3TSPOBRD2BRDT | |
| SCHEMBL15182026 | 0.80 | BRD4 (0.64) | BRD4ADORA3TSPOBRD2BRDT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025076219-A1 | METHODS AND COMPOUNDS FOR MODULATING HUNTINGTON'S DISEASE | Design Therapeutics, Inc. (US) | 2025-04-10 | — | — | WO | disclosed |
| WO-2025076181-A1 | METHODS AND COMPOUNDS FOR MODULATING HUNTINGTON'S DISEASE | Design Therapeutics, Inc. (US) | 2025-04-10 | — | — | WO | disclosed |
| WO-2025076236-A1 | METHODS AND COMPOUNDS FOR MODULATING HUNTINGTON'S DISEASE | Design Therapeutics, Inc. (US) | 2025-04-10 | — | — | WO | disclosed |
| US-20240050576-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2024-02-15 | — | — | US | disclosed |
| US-20230149550-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-05-18 | — | — | US | disclosed |
| US-20230149550-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-05-18 | — | — | US | disclosed |
| EP-4100404-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| WO-2021158707-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. (US) | 2021-08-12 | — | — | WO | disclosed |
| WO-2021158707-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. (US) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149550-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | DMPK, DTYMK, MYCBP | BRD4 928/4885ADORA3 4607/4885TSPO 1781/4885 |
| US-20240050576-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | ZFX, GRN, F13B | BRD4 930/4885ADORA3 4476/4885TSPO 1625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.